Cagrilintide 10 mg/ml by Dragon Pharma is a synthetic long-acting amylin analog studied for its ability to suppress appetite and promote sustained weight reduction. Acting on the amylin receptors in the brain and gastrointestinal system, Cagrilintide is gaining attention in metabolic and obesity-related research protocols for its role in enhancing satiety and reducing food intake without altering lean muscle mass.
Mechanism of Action
Cagrilintide mimics the activity of the endogenous hormone amylin, which is co-secreted with insulin in response to food intake. It activates amylin receptors in the area postrema and nucleus tractus solitarius of the brain, regions involved in regulating satiety, gastric emptying, and caloric intake. This effect leads to a delayed gastric motility response and earlier onset of meal satisfaction, contributing to reduced caloric consumption.
In combination studies with GLP-1 receptor agonists (e.g., semaglutide), Cagrilintide has demonstrated additive or synergistic effects on weight loss and glucose homeostasis. Preclinical data also support its potential in insulin sensitivity modulation and adiposity reduction, making it a promising compound in obesity and type 2 diabetes research.
Key Features & Benefits
- Amylin Receptor Activation: Targets central and peripheral pathways involved in hunger and satiety regulation.
- Supports Appetite Control Research: Studied for its ability to reduce caloric intake and body fat mass.
- Potential Weight Management Synergy: When paired with GLP-1 analogs, may amplify weight loss in preclinical models.
- Non-Stimulant Approach: Modulates metabolic hormones without sympathetic nervous system activation.
- Dragon Pharma Precision: Manufactured under high-purity protocols for consistency in laboratory applications.
Legal Disclaimer
Disclaimer: Cagrilintide is intended for laboratory research purposes only. It is not approved for human use, therapeutic application, or veterinary procedures. Handle under proper lab conditions by certified personnel.
Frequently Asked Questions
Cagrilintide is studied in research settings for appetite suppression, weight loss, and metabolic regulation by targeting amylin receptors.
Both peptides work via different pathways—Cagrilintide through amylin receptors, and Semaglutide through GLP-1. Combined, they may offer superior weight loss results than either alone.
In studies, subjects using Cagrilintide showed significant reductions in body weight over 20–40 weeks, though results depend on dosage and study conditions.
Cagrilintide is also known as AM833 in clinical literature. It has not yet been approved under a commercial brand for general pharmaceutical use.
